Need Support?
Toxicology billing carries a compliance burden unlike almost any lab discipline. Presumptive-versus-definitive testing, tiered G-codes, per-day limits, and medical necessity documentation aren’t rules generalists track. In pain management and substance use settings, where testing happens nearly every visit, small errors compound fast. Audits reveal years of loss, one miscoded tier at a time.
Definitive Testing Tier Miscoding
Missing Medical Necessity Documentation for Definitive Testing
Presumptive & Definitive Same-Day Billing Conflicts
Frequency Limitation Violations
Specimen Validity & Confirmation Bundling Errors
Point-of-care and lab-based qualitative screening across drug classes including opioids, amphetamines, benzodiazepines, cannabinoids, cocaine metabolites, and barbiturates, reported by direct optical observation (80305), instrument chemistry analyzer (80306), or immunoassay with chromatography capability (80307).
Only one presumptive code may be billed per patient per day regardless of how many drug classes were screened --- billing more than one presumptive code on the same date of service is a routine, easily flagged overbilling pattern.
Definitive, quantitative identification of individual drugs and metabolites by GC/MS or LC/MS, tiered strictly by the number of drug classes tested: G0480 (1-7 classes), G0481 (8-14 classes), G0482 (15-21 classes), and G0483 (22 or more classes).
Tier selection must match the exact number of drug classes ordered, tested, and documented in the chart --- billing a higher tier than what was clinically performed is one of the most frequently cited findings in toxicology payment integrity audits.
Non-Medicare definitive testing reported per drug class or category rather than by tier, including alcohol biomarkers (80320-80321), amphetamines (80324-80326), benzodiazepines (80346), buprenorphine (80348), fentanyl (80354), and opioids and opiate analogs (80361-80365).
Each drug class is billed once per date of service no matter how many individual drugs within that class were identified --- commercial payers routinely reject claims that itemize every analyte within a single class separately.
Ethanol screening (80320), ethyl glucuronide and ethyl sulfate biomarker testing for extended abstinence monitoring (80321), and breath alcohol testing (82075) used across SUD monitoring, legal, and DOT-regulated testing contexts.
Ethyl glucuronide and ethyl sulfate testing is frequently denied for medical necessity when ordered as routine surveillance without a documented abstinence-monitoring treatment plan tied to the order.
Baseline and periodic presumptive screening at scheduled visits, definitive confirmation testing triggered by unexpected results or adherence concerns, and monitoring panels aligned to each patient's specific prescribed medication regimen under chronic opioid therapy.
Medicare and most commercial LCDs require a documented risk assessment and a stated clinical reason for escalating to definitive testing --- claims missing that link are among the most commonly denied in pain management toxicology.
Admission baseline panels, ongoing adherence monitoring for buprenorphine, methadone, and naltrexone, and unexpected-result confirmation testing across residential, outpatient, and office-based MAT settings.
Many state Medicaid programs and commercial payers cap definitive testing frequency for SUD treatment patients --- billing beyond those caps without a documented change in clinical status is a leading denial driver in behavioral health toxicology.
Federally mandated DOT and non-DOT workplace drug testing panels, chain-of-custody specimen handling and documentation, and forensic toxicology testing performed for legal or regulatory proceedings.
DOT-regulated and forensic specimens require unbroken chain-of-custody documentation attached to every claim --- a missing custody form is grounds for both payment denial and disqualification of the result in a legal proceeding.
pH, creatinine, specific gravity, and oxidant or adulterant testing performed to confirm a urine specimen's authenticity and integrity before any drug testing result is reported.
CMS and most commercial payers bundle specimen validity testing into the presumptive or definitive drug testing code --- billing it separately under codes like 81007 or 83986 is a routine, easily detected overbilling pattern that draws payer attention fast.
TransLabs’ specialized RCM services are built exclusively for labs, addressing the unique challenges that generalist billers miss. We provide end-to-end revenue cycle solutions designed specifically to turn laboratory complexity into profitability.
Complete payer enrollment, CLIA certification management, and network participation setup across all insurance carriers. TransLabs manages every credentialing detail so that your laboratory gets paid in-network from day one without any administrative delays.
Real-time insurance verification, benefits investigation, and prior auth completed before specimen processing begins. Confirming coverage upfront eliminates preventable denials and protects your lab from unexpected reimbursement failures.
Patient registration, appointment coordination, insurance verification, and customer service excellence managed by experienced laboratory billing professionals. A well-run front office reduces downstream billing errors and creates a better experience.
TransLabs provides expert RCM services to clinical laboratories in all 50 states, delivering the same exceptional results whether you’re a community hospital lab or a large reference facility. We bring specialized lab billing expertise to facilities nationwide, combining remote efficiency with hands-on partnership.
Each Medicare Administrative Contractor maintains its own LCD governing presumptive and definitive urine drug testing, specifying covered ICD-10 diagnoses, documentation expectations, and utilization controls. These policies differ by MAC and change without notice. TransLabs maintains live LCD databases and validates diagnosis-to-test linkage on every Medicare claim before submission.
Medicare requires the medical record to clearly state why definitive confirmation testing was necessary, an unexpected presumptive result, an adherence concern, or a safety risk, not simply that a screen was performed. TransLabs builds documentation prompts into your ordering workflow so the clinical rationale is captured before the claim is ever submitted.
Medicare and most commercial payers cap how often presumptive and definitive testing can be billed for the same beneficiary within a defined period, often tied to a documented risk stratification score. TransLabs monitors each patient's testing history against these limits and flags orders before they exceed what a payer will cover.
When a definitive testing tier or drug class panel may not meet medical necessity criteria under the applicable LCD, a valid ABN must be issued before the specimen is collected. TransLabs implements ABN workflows into front-end intake specifically for pain management and SUD treatment settings where this risk is highest.
The CLFS sets Medicare payment rates for presumptive and definitive drug testing codes and updates annually on January 1. TransLabs monitors CLFS changes, updates billing tables immediately at each rate change, and identifies when a payer is paying below CLFS rates.
Laboratories meeting the applicable laboratory definition under the Protecting Access to Medicare Act carry mandatory private payer data reporting obligations for drug testing codes during designated collection periods. TransLabs tracks your PAMA obligations and ensures accurate, on-time reporting.
The Office of Inspector General's annual Work Plan has repeatedly flagged high-tier definitive drug testing and pain management/SUD-related billing patterns for active audit scrutiny. TransLabs builds compliance protocols specifically around current OIG focus areas to reduce your audit exposure before it becomes a problem.
Most billing companies treat toxicology labs like any outpatient client. They’re not. Toxicology billing has its own tiered coding, documentation standards, frequency/utilization rules, and payer scrutiny in pain management and SUD settings. TransLabs’ team works only in drug testing; no divided attention, no generalist assumptions.
Dedicated billing specialist assigned to your lab or clinic
Complimentary 12-month claims audit across Medicare, Medicaid, and commercial payers
Uncover your top 3 revenue leaks (tier miscoding, documentation gaps, frequency violations)
Custom strategy tailored to your test menu and EHR/LIS software
Live in 24 hours with no contracts and no upfront fees
Pay only a percentage of what we collect for you